Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. (Nasdaq: GANX) is a clinical-stage biotechnology company whose news flow is closely tied to the development of its lead drug candidate, GT-02287, and to progress in its broader allosteric small molecule pipeline. The company focuses on next generation allosteric therapies targeting neurodegenerative diseases, rare genetic disorders and oncology, with a primary emphasis on Parkinson’s disease.
News about Gain Therapeutics frequently covers clinical milestones for GT-02287, including updates from its Phase 1 and Phase 1b studies in people with Parkinson’s disease with or without a GBA1 mutation. Press releases have detailed safety and tolerability findings, exploratory biomarker data such as reductions in glucosylsphingosine (GluSph) in cerebrospinal fluid, and observations related to Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) scores. These items provide insight into how the company interprets GT-02287’s potential disease-modifying effects and mechanism of action.
Investors and observers can also expect regular announcements on preclinical research and scientific presentations. Gain Therapeutics reports data from preclinical models that explore GCase modulation, mitochondrial and lysosomal health, and neuroprotection in Parkinson’s disease. Poster presentations at scientific meetings, such as Neuroscience conferences and Parkinson’s-focused congresses, are common subjects of the company’s news releases.
Additional news items include corporate updates and financial disclosures, such as quarterly financial results, capital raises, changes in board composition, and shareholder meeting outcomes. The company also issues notices about participation in investor conferences, key opinion leader (KOL) events, and webinars that discuss biomarkers, clinical endpoints and emerging data from GT-02287 studies.
For readers following GANX, the news page provides a centralized view of clinical trial progress, scientific data, regulatory and corporate developments, and event participation related to Gain Therapeutics’ efforts in allosteric small molecule drug development.
Gain Therapeutics (NASDAQ: GANX) has received approval to initiate a Phase 1b clinical trial in Australia for GT-02287, its lead candidate for treating Parkinson's disease (PD). The trial follows a successful Phase 1 study where GT-02287 demonstrated safety, tolerability, and >50% increase in GCase activity. The Phase 1b trial will assess safety and tolerability in PD patients over three months of dosing at 13.5 mg/kg/day, along with biomarker evaluation.
The company expects to complete enrollment in spring 2025, with data anticipated by mid-2025. The trial will be conducted across seven Australian sites, focusing on both GBA1 and idiopathic Parkinson's disease patients. Secondary endpoints include pharmacokinetics, GCase modulation, and substrate levels in plasma and cerebrospinal fluid.
Gain Therapeutics (Nasdaq: GANX), a clinical-stage biotechnology company, has announced its participation in Biotech Showcase 2025. Gene Mack, the Company's Chief Financial Officer and Interim Chief Executive Officer, will deliver a corporate presentation featuring their lead drug candidate GT-02287 and the Magellan Drug Discovery Platform.
The presentation is scheduled for Tuesday, January 14, at 9:30am PT in the Yosemite A track at the Hilton San Francisco Union Square. The Biotech Showcase, jointly produced by Demy-Colton and EBD Group, is an investor-focused conference that facilitates networking between executives and investors to promote therapeutic development and investment opportunities.
Gain Therapeutics (GANX) reported Q3 2024 financial results and provided updates on GT-02287, its lead candidate for Parkinson's disease treatment. The Phase 1 study showed a 53% increase in GCase activity with favorable safety in healthy volunteers. The company plans to initiate a Phase 1b trial in Parkinson's patients by end of 2024. Financial highlights include R&D expenses of $2.6M (up $0.3M YoY), G&A expenses of $1.8M (down $0.7M YoY), and cash position of $12M as of September 30, 2024. Net loss was $0.17 per share compared to $0.37 in Q3 2023.
Gain Therapeutics (NASDAQ: GANX) presented data at the 36th EORTC-NCI-AACR Symposium showcasing their allosteric inhibitor GT-03842, identified through their Magellan Drug Discovery Platform. The compound effectively targets and inhibits DDR2 phosphorylation, a protein associated with various cancer types and tumor progression. GT-03842 demonstrated dose-dependent inhibition in both HEK293 cells and a metastatic breast cancer model. The compound's unique mechanism, targeting outside the kinase domain, suggests potential advantages over traditional kinase inhibitors, including enhanced selectivity and reduced resistance.
Gain Therapeutics (Nasdaq: GANX) announced a poster presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, from October 23-25, 2024. The poster will showcase the use of Gain's Magellan platform to discover novel allosteric discoidin domain receptor 2 (DDR2) inhibitors.
DDR2 is implicated in various cancer types and plays a important role in tumor progression. Allosteric small molecule inhibitors have the potential to overcome resistance and offer improved selectivity and safety compared to traditional kinase inhibitors. The presentation, titled 'Identification of allosteric inhibitors targeting Discoidin Domain Receptor 2 (DDR2)', will be given by Sara Cano-Crespo, Ph.D., from Gain Therapeutics during the Molecular Targeted Agents poster session on October 23, 2024, at 11am CEST.
Gain Therapeutics, Inc. (Nasdaq: GANX) has announced that its Chief Medical Officer, Jonas Hannestad, M.D., Ph.D., will present at the Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference on October 17, 2024, in New York City. The presentation will focus on the company's clinical stage lead drug candidate GT-02287, which is being developed for the treatment of Parkinson's disease.
Dr. Hannestad's oral presentation, titled 'Brain-penetrant small molecule GT-02287 is well-tolerated in healthy volunteers, shows GCase target engagement, and achieves therapeutic exposures shown to modulate PD pathobiology in preclinical models,' will be part of the conference's first session, 'Progress in the Therapeutics Pipeline.' The presentation will include Phase 1 data for GT-02287 and recent preclinical findings.
The Parkinson's Disease Therapeutics Conference is the only global event focused exclusively on Parkinson's disease drug development, bringing together 300 research and clinical development professionals from academia and industry to showcase innovative research from MJFF's portfolio.
Gain Therapeutics presented new preclinical data for GT-02287 at the Society for Neuroscience 2024 conference. The data demonstrates disease-modifying activity in both GBA-1 and idiopathic Parkinson's disease models. Key findings include:
1. Persistent rescue of motor and cognitive function after GT-02287 discontinuation
2. Improved mitochondrial function and neuroprotection in GBA1-Parkinson's disease models
3. Reduction in Tau accumulation in GBA-1 mutation and wild type cell lines
The results suggest GT-02287's potential as a disease-modifying therapy for Parkinson's disease and possibly Alzheimer's disease and other tauopathies. The compound showed positive effects on mitochondrial and lysosomal health, addressing the disease cascade resulting from GCase dysfunction.
Gain Therapeutics, a clinical-stage biotechnology company, announced participation in two upcoming investor conferences. Gene Mack, interim CEO and CFO, will represent the company at the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, engaging in one-on-one meetings and a panel on 'Emerging Frontiers in Neuroscience'. He will also attend the 2024 Maxim Healthcare Virtual Summit on October 15, participating in a fireside chat with Jason McCarthy, Ph.D., from Maxim Group. Interested attendees can sign up on M-Vest for updates.
Gain Therapeutics presented Phase 1 data for GT-02287, its lead drug candidate for Parkinson's disease, at the International Congress of Parkinson's Disease and Movement Disorders. The study demonstrated that GT-02287 was safe and well-tolerated in healthy volunteers, with no serious adverse events. Notably, the drug increased GCase activity by approximately 30% in subjects who received GT-02287, indicating target engagement. The drug also showed CNS exposure, with measurable levels in cerebrospinal fluid.
The company plans to initiate a trial in Parkinson's disease patients by the end of Q4 2024, aiming to demonstrate safety, tolerability, and obtain proof of mechanism based on relevant biomarkers. Gain Therapeutics remains optimistic about GT-02287's potential as a disease-modifying treatment for Parkinson's disease.
Gain Therapeutics (Nasdaq: GANX) announced a virtual webinar on September 30, 2024, at 8:30 am ET to discuss results from the Phase 1 study of GT-02287, their novel GCase-targeting small molecule therapy for Parkinson's disease. The company will present positive results recently shared at the International Congress of Parkinson's Disease and Movement Disorders® (MDS) and outline the design of an upcoming Phase 1b trial in Parkinson's disease patients.
The webinar will include a live Q&A session following formal presentations. Interested parties can register for the event or join via the company's website. A replay will be available in the News and Events section of the Gain Therapeutics website after the event.